RESEARCH TRIANGLE PARK, NC--(Marketwire - January 21, 2009) - Pharmaceutical business
intelligence firm Cutting Edge Information announces the release of an
update to its study on drugs in the global cancer market.
Based on an overwhelming response to the first edition of its oncology
market forecast (published in July 2008), the company took a deeper look
into the relevant clinical, commercial, and market trends affecting the
oncology therapeutics today and their impact leading into the next decade.
The new report, "Oncology Roadmap: Brand Spending Benchmarks and Market
Forecast to 2013," details the historical, current and forecasted
performance of more than 120 drugs treating various forms of cancer and the
associated complications involved. Also included are marketed brands,
pipeline products in clinical development, and analysis of the top 13 drug
makers in the oncology therapeutic area.
A complimentary report brochure is available for download at
http://www.cuttingedgeinfo.com/Oncology/index.htm#body
New analysis in the report includes detailed research on the challenges of
pharmaceutical market access, timing, and expenditures for therapies in the
top five oncology treatment areas. The report's structure leads to data
comparisons and analysis across multiple levels. It includes the following
key analyses for existing therapies and anticipated new drugs through 2013:
market expectancy, sales projections, product longevity, positive or
negative clinical trial results, and target patient populations.
"Cancer drugs enter markets that already feature a dizzying assortment of
therapies," said Jeremy Spivey, Cutting Edge Information analyst. "This
report deconstructs the competitive forces at work, and it provides
benchmark spending guidelines for teams building their brand budgets."
The report is organized into brand profiles, drug manufacturer profiles and
benchmark data.
Brand Profiles detail a product's competitive and strategic positioning,
market opportunities, and patent and litigation data. Profiles include the
following information:
-- Drug's current and projected competitive strength
-- Current/projected sales position within its class
-- Sales projection charts for the next four to seven years
-- Assessment of competition
-- Materiality charts
-- Clinical trial information
Company Profiles show breakdowns for seven companies that have established
cancer franchises or exciting development pipelines. Profiles contain:
-- Oncology ranking
-- Overall industry ranking
-- Strengths analysis
-- Growth areas analysis
-- Competition analysis
-- Key products breakdown
For more information about this new report, please visit
http://www.cuttingedgeinfo.com/Oncology/index.htm#body.
Contact Information: CONTACT INFORMATION:
Jeremy Spivey
919-433-0373